Lancet Gastroenterology & Hepatology

Article	Citations
GORD: pain, PPIs, and preciseness	1873
Viral hepatitis: time for action	620
Nationwide practice change after early termination of a randomised trial of laparoscopic pancreatoduodenectomy	579
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply	506
Lucky: Learning to Live Again	498
EASL Congress 2024	435
Treatment withdrawal in Crohn's disease: slowly becoming clearer	419
Trends in alcohol-specific deaths in the UK and industry responses	412
Research in Brief	343
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design	285
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma	284
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled	272
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship	259
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11	256
Voices from the frontline: how global funding cuts are reshaping the viral hepatitis response	251
Developing policy for steatotic liver disease: an even better buy?	240
Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30	222
Thanks to our peer reviewers and contributors	215
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial	214
Appendicectomy: a disease-modifying treatment for ulcerative colitis?	214
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium	214
Global multi-stakeholder endorsement of the MAFLD definition	208
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension	206
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study	194
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial	184

Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial	179
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement	173
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t	164
ACG 2024	159
Long-term VEDOKIDS results: implications for practice and research	156
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47	155
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply	138
Management of portal vein thrombosis in cirrhosis	138
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere	135
Water and sanitation for all	132
Endoscopist deskilling: an unintended consequence of AI-assisted colonoscopy?	132
Research in Brief	127
Idiopathic gastroparesis consensus misses the patient's voice	127
Has the time come for a systematic top-down approach in Crohn's disease?	126
Uptick of food allergies in recent years—real or epiphenomenon?	126
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply	124
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis	120
The potential of ctDNA in locoregional therapies for colorectal cancer	119
Local and systemic therapy in liver cancer: the quest for synergy	119
All roads lead to the gut–brain microbiome network	118
Bringing organ preservation closer for selected patients with rectal cancer	117
Rare cause of dysphagia in a young woman	116
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada	115
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial	113
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised p	113
Availability of point-of-care HBV tests in resource-limited settings	105
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)	101
Resmetirom for NASH: balancing promise and prudence	100
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study	99
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study	96
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review	94
Sex and gender in inflammatory bowel disease outcomes and research	93
Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial	93
Lifting the minority tax in gastroenterology and hepatology	92
The Year My Life Went Down the Toilet	90
A women-focused matrix mentorship programme in gastroenterology	89
Management of malignant bowel obstruction – Authors' reply	89
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B	86
Practicalities accessing precision medicine in biliary tract cancer	84
Research in Brief	82
Another arrow in the NASH quiver?	81
18th Congress of the European Crohn's and Colitis Organisation	80
An unusual complication after a variceal glue injection	79
Britta Siegmund: answering the big questions in IBD	78
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions	78
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED	77
Robotic versus laparoscopic surgery for middle and low rectal cancer	76
Managing inflammatory bowel disease: what to do when the best is unaffordable?	74
Scientific and medical evidence informing expansion of hepatitis B treatment guidelines	74
Urgent action needed to achieve viral hepatitis elimination	73

Shitbag: the story of a diagnosis	72
Hypovolaemic phlebotomy for hepatic resection	71
Redefining palliation in malignant gastric outlet obstruction	71
Closing the gender gap: building a successful career and leadership in research as a female gastroenterologist	70
CEND-1: a game changer for pancreatic cancer chemotherapy?	70
The evolving clinical trial landscape in the MENA region	69
Machine learning-based automated sponge cytology for screening of oesophageal squamous cell carcinoma and adenocarcinoma of the oesophagogastric junction: a nationwide, multicohort, prospective study	68
Primary biliary cholangitis and the narrowing gap towards optimal disease control	68
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial	67
The impact of 2025 US NIDDK funding cuts	67
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial	67
Effects of lyophilised faecal filtrate compared with lyophilised donor stool on Clostridioides difficile recurrence: a multicentre, randomised, double-blinded, non-inferiority trial	67
Unifying the approach to tackling inequalities in liver health: learning from working with underserved populations	66
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment de	65
Long-term safety of faecal microbiota transplantation for gastrointestinal diseases in China	65
Research in brief	65
Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma	65
Management of portal vein thrombosis in cirrhosis – Authors' reply	64
Bowel cancer prevention: are we missing an opportunity?	64
Induction of microRNA-124 as a novel therapeutic concept in ulcerative colitis	63
Primary intestinal lymphangiectasia	63
Bringing dietary therapy for eosinophilic oesophagitis under scientific scrutiny	63
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis	63
Lessons learned from the BOSS trial	63
Compensation advised for UK victims of contaminated blood scandal	62
COP27 Climate Change Conference: urgent action needed for Africa and the world	62
The world is failing on hunger	61
Alcohol and health: time for Europe to sober up	60
Research in Brief	60
Correction to Lancet Gastroenterol Hepatol 2023; 8: 908–18	59
Rethinking coeliac disease care: why psychological understanding matters	59
The problem of antimicrobial resistance in chronic liver disease	59
Clinical remission in ulcerative colitis: restoring precision in trial terminology	58
Hypovolaemic phlebotomy in patients undergoing hepatic resection at higher risk of blood loss (PRICE-2): a randomised controlled trial	57
Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework	56
Increasing burden of colorectal cancer in China	55
The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership	55
Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study	55
Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines	55
Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review	54
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease	54
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study	54
The intestinal barrier: a pivotal role in health, inflammation, and cancer	53
PANTS extension study: how best to use anti-TNF drugs in Crohn's disease	52
Does filgotinib work for Crohn's disease?	52
Diet or optimised medical therapy for people with irritable bowel syndrome	52
HIV pre-exposure prophylaxis as an entry point to the elimination of hepatitis B virus	51
Addressing Africa's marginalisation in hepatocellular carcinoma clinical trials	51
Early-onset colorectal cancer: Hollyoaks tackles taboos and raises awareness	49
Watch and wait for rectal cancer: towards data-informed surveillance	49
Lessons and open questions in borderline resectable pancreatic cancer	49
World Hepatitis Day 2025: elimination at a critical juncture	48
Spleen stiffness in portal hypertension algorithms: the next advance	48
Peroral endoscopic myotomy versus pneumatic dilation for achalasia	48
Standardising early liver transplantation for severe alcohol-related hepatitis	47
DEI in gastroenterology and hepatology	47
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection	47
The costs of inadequate toilet coverage in the Philippines	47
Research in Brief	46
The British Association for the Study of the Liver commitment to equality, diversity, and inclusivity	46
The role of [18F]FDG and [18F]FCH PET-CT in hepatocellular carcinoma with cirrhosis	45
Elimination of hepatitis B requires recognition of catastrophic costs for patients and their families	45
Gastroenterology training in Africa: an assessment of curriculum and perception	45
Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics	44
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-contr	44
Pre-emptive TIPS for gastric variceal bleeding in patients with cirrhosis (GAVAPROSEC): an open-label randomised clinical trial	44
Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysis	44
Correction to Lancet Gastroenterol Hepatol 2025; 10: 715–25	44
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised contro	40
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD	39
The liver–brain axis in metabolic dysfunction-associated steatotic liver disease	39
Combination locoregional and systemic therapies in hepatocellular carcinoma	38
Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial	38
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	37
Oncological safety of laparoscopic surgery for low rectal cancer	36
Inequities in alcohol-related harm in the Philippines	35
More is not always better for novel hepatitis B therapies	35
The International Liver Congress 2022	35
Research in Brief	35
Putting steatotic liver disease on the global NCD agenda	34

Inclusion of patients with isolated ulcerative proctitis in clinical trials	34
Research in Brief	34
Correction to Lancet Gastroenterol Hepatol 2025; 10: 634–47	33
Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better	33
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomise	33
An open letter to Gavi: hepatitis B birth dose vaccine can't wait	33
Accelerating point-of-care HCV viral load testing	33
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from	33
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study	33
Launch of the International Living Donor Liver Transplantation Outcomes Registry	33
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial	33
A coordinated multipronged attack: integrated care is the future for gastroenterology	32
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions	32
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial	32
Time for a treat all approach for hepatitis B	32
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis	31
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study	31
The case for reducing the use of diagnostic upper and lower gastrointestinal endoscopy	31
Tackling obesity: drugs are only part of the solution	30
The Liver Meeting 2023	30
Haematopoietic stem-cell transplantation in Crohn's disease	30
Chronic Boom	30
No accident: the UK infected blood scandal	30
A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia	29
Local ablation in pancreatic cancer: some answers and more questions	29
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study	29
Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial	29
Hypovolaemic phlebotomy to reduce the need for perioperative transfusion: a price worth paying?	29
The urgent need to end hepatitis B stigma and discrimination	29
Retina and liver fibrosis screening for patients with type 2 diabetes	29
Refining the faecal incontinence core outcome set – Authors' reply	28
Research in Brief	28
Psychological therapies in inflammatory bowel disease	28
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes	28
Comparison of trends in early-onset colorectal cancer in North America and Europe	27
Vedolizumab in paediatric IBD: a huge step forward but not there yet	26
Terlipressin for hepatorenal syndrome: opportunities and challenges	26
Challenging stigma around alcohol misuse	26
Lessons from a trial of colesevelam for bile acid diarrhoea	25
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia – Authors' reply	25
Séverine Vermeire: advancing patient-centred research in IBD	25
Research in Brief	24
A new chapter in the campaign to eliminate viral hepatitis?	24
Cultural competence in the delivery of nutrition and symptom care in irritable bowel syndrome	23
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated rand	23
Robotic pancreatoduodenectomy: preparing for the future	23
Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study	23
The Liver Meeting 2025	23
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based th	22
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership	22
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial	22
Correction to Lancet Gastroenterol Hepatol 2022; 7: 202–03	22
Research in Brief	21
Expression of concern—Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre random	21
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? – Author's reply	21
Africa must not be left out of the hepatitis B cure era	21
Diet or optimised medical therapy for people with irritable bowel syndrome	21
An important step towards the long-term treatment of eosinophilic oesophagitis	21
No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis	20
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary?	20
Antibiotic treatment versus appendicectomy for acute appendicitis in adults: an individual patient data meta-analysis	20
Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions	20
NAFLD prevalence and severity in overweight and obese populations	20
Are all post-ESWL pancreatitis events clinically significant?	19
Variceal embolisation plus TIPS for variceal bleeding	19
Single CT colonography versus three rounds of faecal immunochemical test for population-based screening of colorectal cancer (SAVE): a randomised controlled trial	19
Financing viral hepatitis: catalysing action for impact	19
Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel	18
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial	18
ASCO Gastrointestinal Cancers Symposium 2026	18
Liver disease admissions in the UK are increasing, urgently needing local and national solutions	18
Research in Brief	18
Africa CDC's viral hepatitis prevention and control programme: a continental initiative to support elimination programmes	18
Non-coeliac gluten sensitivity: from Salerno to Rome	18
Intraoperative fluorescence angiography with indocyanine green to prevent anastomotic leak in rectal cancer surgery (IntAct): an unblinded randomised controlled trial	18
Difficulties in identifying a signal of activity in the adjuvant setting for biliary tract cancer	18
Weighing the benefits of screening for early-onset colorectal cancer	17
Targeting type 2 immune responses to treat eosinophilic gastritis	17
Uncouplers of mitochondrial oxidation in non-alcoholic fatty liver disease	17
An Indigenous First Nations perspective on liver health	16
A path to global cirrhosis health equity	16
The first new drug for progressive familial intrahepatic cholestasis	16
Retina and liver fibrosis screening for patients with type 2 diabetes – Authors' reply	16
Proximal serrated polyp detection rate and interval post-colonoscopy colorectal cancer risk – Authors' reply	16
Preventive cholera vaccination resumes	15
Overcoming the challenges of overtreating and undertreating inflammatory bowel disease	15
The promise of automated liver disease risk stratification in primary care	15
Pathogens don't respect politicians: US federal disruption poses a new threat to global public health	15
Clinical outcomes of untreated adults living with chronic hepatitis B in The Gambia: an analysis of data from the prospective PROLIFICA cohort study	15
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial – Authors' reply	14
Targeting the EGFR signalling pathway in metastatic colorectal cancer	14
Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-infe	14
Who to test and reflex testing for hepatitis D virus infection: evidence and rationale to inform policy recommendations and future directions	14
Global perspectives on sustainable IBD care	14
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial	14